Advancement of therapies for neuroprotection in multiple sclerosis (Q37256701)

19 August 2017

1 reference

title

Advancement of therapies for neuroprotection in multiple sclerosis (English)

1 reference

19 August 2017

0 references

Albert Lo

1

1 reference

19 August 2017

1 September 2008

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

19 August 2017

1 reference

19 August 2017

8

1 reference

19 August 2017

9

1 reference

19 August 2017

1355-1366

1 reference

Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Magnetic resonance spectroscopy as a measure of brain damage in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Secondary progressive multiple sclerosis: current knowledge and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Interferons in relapsing remitting multiple sclerosis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Multiple sclerosis: is there neurodegeneration independent from inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Progression in multiple sclerosis: further evidence of an age dependent process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Axonal transection in the lesions of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Brain atrophy in clinically early relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Inflammation versus neurodegeneration: consequences for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Corticosteroids do not prevent optic nerve atrophy following optic neuritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Molecular pathogenesis of neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

The local differentiation of myelinated axons at nodes of Ranvier

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

General mechanisms of axonal damage and its prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

The role of nitric oxide in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Nitric oxide inhibition of mitochondrial respiration and its role in cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Hypoxia-like tissue injury as a component of multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Flux coupling in a neuronal glutamate transporter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Phenytoin and carbamazepine: potential- and frequency-dependent block of Na currents in mammalian myelinated nerve fibers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Phenytoin protects spinal cord axons and preserves axonal conduction and neurological function in a model of neuroinflammation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Long-term protection of central axons with phenytoin in monophasic and chronic-relapsing EAE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

An in vitro electrophysiological study on the effects of phenytoin, lamotrigine and gabapentin on striatal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Differential inhibition by riluzole, lamotrigine, and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Neuroprotection in multiple sclerosis: therapeutic strategies and clinical trial design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Mechanisms of disease: sodium channels and neuroprotection in multiple sclerosis-current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Carbamazepine and topiramate modulation of transient and persistent sodium currents studied in HEK293 cells expressing the Na(v)1.3 alpha-subunit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Excitatory amino acids as a final common pathway for neurologic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Evidence of elevated glutamate in multiple sclerosis using magnetic resonance spectroscopy at 3 T.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Neurotransmitters in cerebrospinal fluid reflect pathological activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Excitatory amino acids and multiple sclerosis: evidence from cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

White matter NMDA receptors: an unexpected new therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Longitudinal brain volume measurement in multiple sclerosis: rate of brain atrophy is independent of the disease subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Glutamate inhibition in MS: the neuroprotective properties of riluzole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

FK 506 for liver, kidney, and pancreas transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

FK506 requires stimulation of the extracellular signal-regulated kinase 1/2 and the steroid receptor chaperone protein p23 for neurite elongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Inhibition of autoimmune encephalomyelitis by a tetracycline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

The promise of minocycline in neurology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Minocycline up-regulates Bcl-2 and protects against cell death in mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Multiple neuroprotective mechanisms of minocycline in autoimmune CNS inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Glycogen regulation and functional role in mouse white matter

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Beta 2-adrenoceptor involvement in inflammatory demyelination and axonal degeneration in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

A novel endogenous erythropoietin mediated pathway prevents axonal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Sex differences in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Estrogen potentiates treatment with T-cell receptor protein of female mice with experimental encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

A potential role for estrogen in experimental autoimmune encephalomyelitis and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Differential neuroprotective and antiinflammatory effects of estrogen receptor (ER)alpha and ERbeta ligand treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Treatment of multiple sclerosis with the pregnancy hormone estriol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Testosterone treatment in multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Novel mechanisms of estrogen action in the brain: new players in an old story.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Local and target-derived actions of neurotrophins during peripheral nervous system development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Neurotrophins and their receptors: signaling trios in complex biological systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Association of a null mutation in the CNTF gene with early onset of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Low and dysregulated BDNF secretion from immune cells of MS patients is related to reduced neuroprotection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Continued administration of ciliary neurotrophic factor protects mice from inflammatory pathology in experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Reliability of trans-cervical recovery of placental cells from the lower uterine pole using a minimally invasive procedure. Evidence based on fetal sexing and analysis of recovered cell populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Brain derived neurotrophic factor treatment reduces inflammation and apoptosis in experimental allergic encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

The measurement and clinical relevance of brain atrophy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Can clinical outcomes be used to detect neuroprotection in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Modeling axonal degeneration within the anterior visual system: implications for demonstrating neuroprotection in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

Neuroprotective effects and intracellular signaling pathways of erythropoietin in a rat model of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.8.9.1355

10.1586/14737175.8.9.1355

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18759548